Sanjivani Paranteral Ltd
NSE: BSE: 531569
₹160
(-3.00%)
Wed, 06 May 2026, 01:20 am
Market Cap2.01B
PE Ratio24.38
Dividend0.31
Health Technology
Pharmaceuticals: Major
24.5KSanjivani Paranteral Analysis
dividend
- Unable to evaluate Sanjivani Paranteral's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Sanjivani Paranteral's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Sanjivani Paranteral's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Operating cash flow is negative therefore debt is not well covered.
- Sanjivani Paranteral has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
- Sanjivani Paranteral's long term commitments exceed its cash and other short term assets.
- Irrelevant to check if Sanjivani Paranteral's debt level has increased considering it has negative shareholder equity.
- Sanjivani Paranteral has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
- High level of physical assets or inventory.
management
- Ashwani's remuneration is about average for companies of similar size in India.
- Ashwani's compensation has been consistent with company performance over the past year, both up more than 20%.
- Sanjivani Paranteral individual insiders have only sold shares in the past 3 months, but not in substantial volumes.
- The average tenure for the Sanjivani Paranteral management team is less than 2 years, this suggests a new team.
misc
- Sanjivani Paranteral is not covered by any analysts.
past
- Unable to compare Sanjivani Paranteral's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Sanjivani Paranteral does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- It is difficult to establish if Sanjivani Paranteral has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Sanjivani Paranteral improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
- It is difficult to establish if Sanjivani Paranteral has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
- Unable to compare Sanjivani Paranteral's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
- BSE:531569 is up 10% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:531569 is up 10% outperforming the market in India which returned 8% over the past month.
- Sanjivani Paranteral has negative assets, we can't compare the value of its assets to the IN Pharmaceuticals industry average.
- Sanjivani Paranteral is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Sanjivani Paranteral is loss making, we can't compare the value of its earnings to the India market.
- 531569 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 531569 underperformed the Market in India which returned -14.5% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800